H. Lee Moffitt Cancer Center & Research Institute

Physician, Faculty, and Staff

Andy M. Trotti, MD

Andy M. Trotti, MD

Faculty Rank:

Senior Member

Titles:

  • Director Radiation Oncology Clinical Research
  • Principal Investigator, Institutional, RTOG Studies

Department/Program Affiliations:

  • Cutaneous Oncology  
  • Head & Neck Oncology  
  • Experimental Therapeutics  
  • Radiation Oncology  
  • Comprehensive Melanoma Research Center  
  • Risk Assessment,Detection & Intervention  

Primary Address:

H. Lee Moffitt Cancer Center &
Research Institute
12902 Magnolia Drive
Tampa, FL 33612

Consultation/Referral Phone:

(813) 745-8424

USF Affiliations/College Department:

  • Medicine / Oncologic Sciences

University Academic Rank:

Professor

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Andy M. Trotti, MD

Education & Training:

  • M.D., University of Florida, 1984
  • Internship, University of Florida, 1985 - Multidisciplinary Oncology
  • Residency, University of Alabama at Birmingham, 1988 - Radiation Oncology

General Board Certification / SubSpecialty:

  • Radiation Oncology

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Andy M. Trotti, MD

Research Interests:

As one of the longest serving Moffitt physicians, Dr. Trotti is recognized for expertise in head and neck and cutaneous malignancies, and the adverse effects of cancer treatment. He has conducted original and collaborative group clinical trials in head and neck cancer at the Cancer Center for more than 17 years.

Under his leadership, Moffitt became a member of the National Cancer Institute-sponsored Radiation Therapy Oncology Group (RTOG) in 1990 and continues today as one of a select group of active full members. Dr. Trotti serves as institutional principal investigator for RTOG studies. Several of Dr.Trotti's original pilot studies conducted at Moffitt in the areas of fractionation, toxicity interventions, and combined modality therapy have advanced to become national multicenter trials. Dr. Trotti is co-chair of the RTOG Head and Neck Committee. Under his guidance, several of his radiation oncology colleagues at Moffitt have participated in leadership roles within RTOG, including the Quality of Life Committee, Outcomes Committee, Special Populations Committees, and Research Associates Committee. Dr. Zachariah and Dr. Gwede from Radiation Oncology are currently leading a phase III RTOG trial of octreotide in the prevention of radiation-induced diarrhea. As part of the effort to measure outcomes, Darlene Johnson, MBA, and Dr. Trotti developed and validated a radiation-specific quality of life tool currently in use in two national RTOG trials. Dr. Trotti and colleague Dr. Javier Torres-Roca were recently awarded a pilot grant to study genomic predictors of radiosensitivity in RTOG populations.

Dr. Trotti is co-chair of the Health Services Research (HSR) Committees for both the American Society of Therapeutic Radiology and Oncology (ASTRO) and the American Society of Clinical Oncology (ASCO). Dr. Trotti has a unique area of expertise: the recognition, reporting, prevention, and management of the adverse effects of cancer treatment. Dr Trotti assisted the NCI in creating the current NCI dictionary for adverse events (CTCAE). This document has become the international standard for toxicity reporting. He has also led pivotal trials testing iseganan and lisofylline in mucositis. Dr. Trotti is Co-PI of a multicenter phase III randomized trial testing KGF for the reduction of H&N mucositis, sponsored by Amgen and RTOG. Dr. Trotti and colleagues were awarded federal grants to develop electronic methods of grading and reporting toxicity in clinical trials (Safety Profiler).



For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Andy M. Trotti, MD

Publications:

  1. Chung CH, Zhang Q, Hammond EM, Trotti AM, Wang H, Spencer S, Zhang HZ, Cooper J, Jordan R, Rotman MH, Ang KK. Integrating Epidermal Growth Factor Receptor Assay with Clinical Parameters Improves Risk Classification for Relapse and Survival in Head-and-Neck Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2010 Aug. Pubmedid: 20732768.   Pubmed ID: 20732768

  2. Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer. 2010 Apr;18(4):509-522. Pubmedid: 20145956.   Pubmed ID: 20145956

  3. Peters LJ, O'Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, Bernier J, Bourhis J, Yuen K, Fisher R, Rischin D. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol. 2010 Jun;28(18):2996-3001. Pubmedid: 20479390.   Pubmed ID: 20479390

  4. Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, Trotti A, Bernier J, Bourhis J, Ringash J, Henke M, Kenny L. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol. 2010 Jun;28(18):2989-2995. Pubmedid: 20479425.   Pubmed ID: 20479425

  5. Adelstein DJ, Ridge JA, Gillison ML, Chaturvedi AK, D'Souza G, Gravitt PE, Westra W, Psyrri A, Martin Kast W, Koutsky LA, Giuliano A, Krosnick S, Trotti A, Schuller DE, Forastiere A, Dansky Ullmann C. Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck. 2009 Nov;31(11):1393-1422. Pubmedid: 19787782.   Pubmed ID: 19787782

  6. Forastiere AA, Trotti AM. Searching for Less Toxic Larynx Preservation: A Need for Common Definitions and Metrics. J Natl Cancer Inst. 2009 Feb;101(3):129-131. Pubmedid: 19176460.   Pubmed ID: 19176460

  7. Hensley M, Hagerty K, Kewalramani T, Green D, Meropol N, Wasserman T, Cohen G, Emami B, Gradishar W, Mitchell R, Thigpen J, Trotti A, von HoffD, Schuchter L. American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants. J Clin Oncol. 2009 Jan;27(1):127-145. Pubmedid: 19018081.   Pubmed ID: 19018081

  8. Le QT, Harris J, Magliocco AM, Kong CS, Diaz R, Shin B, Cao H, Trotti A, Erler JT, Chung CH, Dicker A, Pajak TF, Giaccia AJ, Ang KK. Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. J Clin Oncol. 2009 Sep;27(26):4281-4286. Pubmedid: 19667273.   Pubmed ID: 19667273

  9. Murphy BA, Beaumont JL, Isitt J, Garden AS, Gwede CK, Trotti AM, Meredith RF, Epstein JB, Le QT, Brizel DM, Bellm LA, Wells N, Cella D. Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy. J Pain Symptom Manage. 2009 Oct;38(4):522-532. Pubmedid: 19608377.   Pubmed ID: 19608377

  10. Rosenthal DI, Harris J, Forastiere AA, Weber RS, Ridge JA, Myers JN, Garden AS, Kuettel MR, Sidhu K, Schultz CJ, Trotti A, Ang KK. Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients With resected high-risk dead and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. J Clin Oncol. 2009 Oct;27(28):4727-4732. Pubmedid: 19720915.   Pubmed ID: 19720915

  11. Salama JK, Haddad RI, Kies MS, Busse PM, Dong L, Brizel DM, Eisbruch A, Tishler RB, Trotti AM, Garden AS. Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009 Nov;75(3):725-733. Pubmedid: 19362781.   Pubmed ID: 19362781

  12. Tanvetyanon T, Padhya T, McCaffrey J, Zhu W, Boulware D, Deconti R, Trotti A. Prognostic Factors for Survival After Salvage Reirradiation of Head and Neck Cancer. J Clin Oncol. 2009 Apr;27(12):1983-1991. Pubmedid: 19289616.   Pubmed ID: 19289616

  13. Tanvetyanon T, Qin D, Padhya T, Kapoor R, McCaffrey J, Trotti A. Survival outcomes of squamous cell carcinoma arising from sinonasal inverted papilloma: report of 6 cases with systematic review and pooled analysis. Am J Otolaryngol. 2009 Jan;30(1):38-43. Pubmedid: 19027511.   Pubmed ID: 19027511

  14. Tanvetyanon T, Qin D, Padhya T, McCaffrey J, Zhu W, Boulware D, DeConti R, Trotti A. Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch Otolaryngol Head Neck Surg. 2009 Jul;135(7):687-692. Pubmedid: 19620591.   Pubmed ID: 19620591

  15. Bensinger W, Schubert M, Ang K, Brizel D, Brown E, Eilers J, Elting L, Mittal B, Schattner M, Spielberger R, Treister N, Trotti AM 3rd. NCCN Task Force Report. prevention and management of mucositis in cancer care. J Natl Compr Canc Netw. 2008 Jan;6:S1-S21. Pubmedid: 18289497.   Pubmed ID: 18289497

  16. Garden AS, Harris J, Trotti A, Jones CU, Carrascosa L, Cheng JD, Spencer SS, Forastiere A, Weber RS, Ang KK. Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14). Int J Radiat Oncol Biol Phys. 2008 Aug;71(5):1351-1355. Pubmedid: 18640496. Pmcid: PMC2582390.   Pubmed ID: 18640496

  17. Machtay M, Moughan J, Trotti A, Garden A, Weber R, Cooper J, Forastiere A, Ang K. Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis. J Clin Oncol. 2008 Jul;26(21):3582-3589. Pubmedid: 18559875.   Pubmed ID: 18559875

  18. Calvin D, Hammond M, Pajak T, Trotti A, Meredith R, Rotman M, Jones C, Byhardt R, Demas W, Ang K, Fu K. Microvessel density >or=60 does not predict for outcome after radiation treatment for locally advanced head and neck squamous cell carcinoma: results of a correlative study from the Radiation Therapy Oncology Group (RTOG) 90-03 Trial. Am J Clin Oncol. 2007 Aug;30(4):406-419. Pubmedid: 17762442.   Pubmed ID: 17762442

  19. Trotti A, Colevas A, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol. 2007 Nov;25(32):5121-5127. Pubmedid: 17991931.   Pubmed ID: 17991931

  20. Trotti A, Pajak T, Gwede C, Paulus R, Cooper J, Forastiere A, Ridge J, Watkins-Bruner D, Garden A, Ang K, Curran W. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol. 2007 Jul;8(7):613-624. Pubmedid: 17543584.   Pubmed ID: 17543584

  21. Chen Y, Trotti A, Coleman C, Machtay M, Mirimanoff R, Hay J, O'brien P, El-Gueddari B, Salvajoli J, Jeremic B. Adverse event reporting and developments in radiation biology after normaltissue injury: International Atomic Energy Agency consultation. Int J Radiat Oncol Biol Phys. 2006 Apr;64(5):1442-51. Epub 2. Pubmedid: 16414207.   Pubmed ID: 16414207

  22. Forastiere A, Trotti A, Pfister D, Grandis J. Head and neck cancer: recent advances and new standards of care. J Clin Oncol. 2006 Jun;24(17):2603-2605. Pubmedid: 16763271.   Pubmed ID: 16763271

  23. Wood G, Casey L, Trotti A. Skin changes. Cancer Treat Res. 2006;128:171-181. Pubmedid: 16335018.   Pubmed ID: 16335018

  24. Ang K, Harris J, Garden A, Trotti A, Jones C, Carrascosa L, Cheng J, Spencer S, Forastiere A, Weber R. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. J Clin Oncol. 2005 May;23(13):3008-3015. Pubmedid: 15860857.   Pubmed ID: 15860857

  25. Soares HP, Kumar A, Daniels S, Swann S, Cantor A, Hozo I, Clark M, Serdarevic F, Gwede C, Trotti A, Djulbegovic B. Evaluation of new treatments in radiation oncology: are they better than standard treatments. JAMA. 2005 Feb;293(8):970-978. Pubmedid: 15728168.   Pubmed ID: 15728168

  26. Trotti A, Bentzen S. The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol. 2004;22:19-22. Pubmedid: 14657230.   Pubmed ID: 14657230

  27. Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R, Pajak T, Fleming T, Henke M, Bourhis J, Rosenthal D, Junor E, Cmelak A, Sheehan F, Pulliam J, Devitt-Risse P, Fuchs H, Chambers M, O'Sullivan B, Ang K. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys. 2004;58(3):674-681. Pubmedid: 14967419.   Pubmed ID: 14967419

  28. Trotti A, Bellm L, Epstein J, Frame D, Fuchs H, Gwede C, Komaroff E, Nalysnyk L, Zilberberg M. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003;66(3):253-262. Pubmedid: 12742264.   Pubmed ID: 12742264

  29. Trotti A, Colevas A, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman C, Rubin P. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176-181. Pubmedid: 12903007.   Pubmed ID: 12903007

  30. Gwede C, Johnson D, Daniels S, Trotti A. Assessment of toxicity in cooperative oncology clinical trials: the long and short of it. J Oncol Manag. 2002;11(2):15-21. Pubmedid: 11989815.   Pubmed ID: 11989815

  31. Rose-Ped A, Bellm L, Epstein J, Trotti A, Gwede C, Fuch H. Complications of radiation therapy for head and neck cancer. The patient's perspective. Cancer Nurs. 2002;25(6):461-467. Pubmedid: 12464838.   Pubmed ID: 12464838

  32. Trotti A. The evolution and application of toxicity criteria. Semin Radiat Oncol. 2002;12(1):1-3. Pubmedid: 11917276.   Pubmed ID: 11917276

  33. Kim C, Yeatman T, Coppola D, Trotti A, Williams B, Barthel J, Dinwoodie W, Karl R, Marcet J. Local excision of T2 and T3 rectal cancers after downstaging chemoradiation. Ann Surg. 2001;234(3):352-358. Pubmedid: 11524588.   Pubmed ID: 11524588

  34. Fu K, Pajak T, Trotti A, Jones C, Spencer S, Phillips T, Garden A, Ridge J, Cooper J, Ang K. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation to two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48(1):7-16. Pubmedid: 10924966.   Pubmed ID: 10924966

  35. Herskovic A, Scott C, Demas W, Gaspar L, Trotti A. Accelerated hyperfractionation for bronchogenic cancer: Radiation Therapy Oncology Group 9205. Am J Clin Oncol. 2000;23(2):207-212. Pubmedid: 10776986.   Pubmed ID: 10776986

  36. Smith D, Messina J, Perrott R, Berman C, Reintgen D, Cruse C, Glass F, DeConti R, Trotti A, Fenske N. Clinical approach to neuroendocrine carcinoma of the skin (Merkel cell carcinoma). Cancer Control. 2000;7(1):72-83. Pubmedid: 10740663.   Pubmed ID: 10740663

  37. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormic B, Morris M, Rich T, Shipley W, Curran W. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47(1):13-47. Pubmedid: 10758303.   Pubmed ID: 10758303

  38. Trotti A. Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys. 2000;47(1):1-12. Pubmedid: 10758302.   Pubmed ID: 10758302

  39. Flood W, Lee D, Trotti A, Spencer S, Murphy B, Khuri F, DeConti R, Wheeler R, Forastiere A. Multimodality therapy of patients with locally advanced squamous cell cancer of the head and neck: preliminary results of two pilot trials using paclitaxel and cisplatin. Semin Rad Oncol. 1999;9(2):61-69. Pubmedid: 10210542.   Pubmed ID: 10210542

  40. Johnson D, Roberts C, Trotti, III A, Greenberg H. Professional satisfaction among radiation therapists: a regional survey. Radiation Therapist. 1998;7(1):103-110. Pubmedid: noPMID.  

  41. Sekharam M, Trotti, III A, Cunnick J, Wu J. Supression of fibroblast cell cycle progression in G1 phase by N-acetylcysteine. Toxicol Appl Pharmacol. 1998;149:210-216. Pubmedid: 9571990.   Pubmed ID: 9571990

  42. Trotti A, Johnson D, Gwede C, Casey L, Sauder B, Cantor A. Development of a head and neck companion module for the quality of life-radiation therapy instrument (QOL-RTI). Int J Radiat Oncol Biol Phys. 1998;42(2):257-261. Pubmedid: 9788402.   Pubmed ID: 9788402

  43. Trotti, III A, Klotch D, Endicott J, Ridley M, Cantor A. Postoperative accelerated radiotherapy in high-risk squamous cell carcinoma of the head and neck: long-term results of a prospective trial. Head Neck. 1998;20(2):119-123. Pubmedid: 9484942.   Pubmed ID: 9484942

  44. Balducci L, Trotti, III A. Organ preservation: an effective and safe form of cancer treatment. Clin Geriatr Med. 1997;13(1):185-201. Pubmedid: 8995107.   Pubmed ID: 8995107

  45. Cruse C, Reintgen D, Glass F, Messina J, Trotti, III A, DeConti R. Clinical practice guidelines: neuroendocrine tumors of the skin. Cancer Control. 1997;4:258-260. Pubmedid: noPMID.  

  46. Futran N, Trotti, III A, Gwede C. Pentoxifylline in the treatment of radiation-related soft tissue injury: preliminary observations. Lancet. 1997;107(3):391-395. Pubmedid: 9121320.   Pubmed ID: 9121320

  47. Trotti, III A. Toxicity antagonists in cancer therapy. Curr Opin Oncol. 1997;9:569-578. Pubmedid: 9370079.   Pubmed ID: 9370079

  48. Vaidynathan M, Clarke L, Velthuizen R, Phuphanich S, Bensaid A, Hall L, Bezdek J, Greenberg H, Trotti, III A, Silbiger M. Comparison of supervised MRI segmentation methods for tumor volume determination during therapy. Magn Reson Imaging. 1995;13(5):719-728. Pubmedid: 8569446.   Pubmed ID: 8569446

  49. Endicott J, Trotti III A. Organ preservation in patients with head and neck cancer. Cancer Control. 1994;1(1):13-19.  

  50. Gupta S, Spiers A, Saba H, Moscinski L, Lyman G, Diaz J, Trotti, III A, Ridley M, Endicott J, Sanderson R. Extranodal lymphomas of the head and neck (ELHN): A six-year survey. Blood. 1993;82:2245-2245.  

  51. Trotti III A, Klotch D, Endicott J, Ridley M, Greenberg H. A prospective trial of accelerated radiotherapy in the postoperative treatment of high risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1993;26(1):13-21. Pubmedid: 8482619.   Pubmed ID: 8482619

  52. Trotti III A, Peters L. Role of radiotherapy in the primary management of mucosal melanoma of the head and neck. Semin Surg Oncol. 1992;9(3):246-250.  

  53. Trotti III A, Peters L. The role of radiotherapy in the primary management of muscosal melanoma. Ann Plast Surg. 1992;28(1):39-44.  

  54. Johnson D, Casey L, Gwede C, Friedland J, Trotti, III A. 1996;850-851.  

Andy M. Trotti, MD

Below is a list of active grants where the faculty member is the Principal Investigator. Grants are sorted by sponsor and then sorted by start date, with the more recent grant shown first.

Radiation Therapy Oncology Group

0488
Sponsor: Amer College of Radiology / Nat Institutes of Health
Project Dates: April 1, 2008 to December 31, 2014
Earned to Date: $0

Caphosol Study Biostatistics
Sponsor: EUSA Pharmaceuticals, Inc.
Project Dates: June 1, 2010 to May 31, 2011
Annual Direct Cost: $100,465
Annual Total Cost: $134,316
Project Total: $51,975

Preoperative radiotherapy for primary soft tissue sarcomas of the extremity
Sponsor: RTOG
Project Dates: June 12, 2009 to June 11, 2011
Earned to Date: $22,000

Concurrent Accelerated XRT & Cisplatin VS Concurrent Accelerated XRT, Cisplatin & Cetuxamab in Head & Neck CA
Sponsor: RTOG
Project Dates: October 11, 2006 to October 10, 2011
Earned to Date: $4,600

Physician/Faculty  Contact Form

© Copyright 1996 - 2010 H. Lee Moffitt Cancer Center & Research Institute